{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T02:48:15Z","timestamp":1793155695899,"version":"4.5.0"},"reference-count":10,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,29]],"date-time":"2019-10-29T00:00:00Z","timestamp":1572307200000},"content-version":"vor","delay-in-days":850,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1093\/annonc\/mdx193","type":"journal-article","created":{"date-parts":[[2017,4,21]],"date-time":"2017-04-21T11:08:11Z","timestamp":1492772891000},"page":"1569-1575","source":"Crossref","is-referenced-by-count":107,"title":["Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study"],"prefix":"10.1016","volume":"28","author":[{"given":"M.E.","family":"Pavel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Baudin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.E.","family":"\u00d6berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.D.","family":"Hainsworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Voi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Rouyrre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Peeters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.J.","family":"Gross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.C.","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdx193_bb0010","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after \"carcinoid\": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States","volume":"26","author":"Yao","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx193_bb0015","unstructured":"National Comprehensive Cancer Network. Clinical practice guideline in oncology. Neuroendocrine tumors version 2. 2014; http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/neuroendocrine.pdf (3 January 2017, last date accessed)."},{"key":"10.1093\/annonc\/mdx193_bb0020","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(11)61742-X","article-title":"Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study","volume":"378","author":"Pavel","year":"2011","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdx193_bb0025","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment Of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdx193_bb0030","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1093\/jnci\/djp369","article-title":"Detecting an overall survival benefit that is derived from progression-free survival","volume":"101","author":"Broglio","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdx193_bb0035","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1200\/JCO.2010.33.2056","article-title":"Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting","volume":"29","author":"Kulke","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx193_bb0040","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1634\/theoncologist.2012-0434","article-title":"Targeted therapies in neuroendocrine tumors (NET): clinical trial challenges and lessons learned","volume":"18","author":"Yao","year":"2013","journal-title":"Oncologist"},{"key":"10.1093\/annonc\/mdx193_bb0045","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1159\/000381930","article-title":"Carcinoid heart disease: from pathophysiology to treatment-\u2018Something in the way it moves'","volume":"101","author":"Grozinsky-Glasberg","year":"2015","journal-title":"Neuroendocrinology"},{"key":"10.1093\/annonc\/mdx193_bb0050","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.3748\/wjg.v22.i6.2118","article-title":"Healthcare and economic impact of diarrhea in patients with carcinoid syndrome","volume":"22","author":"Broder","year":"2016","journal-title":"World J Gastroenterol"},{"key":"10.1093\/annonc\/mdx193_bb0055","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","article-title":"Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study","volume":"387","author":"Yao","year":"2016","journal-title":"Lancet"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375341932280X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375341932280X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/28\/7\/1569\/17928327\/mdx193.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T08:25:11Z","timestamp":1624695911000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092375341932280X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":10,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["S092375341932280X"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdx193","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]}}}